1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

L. Paz-Ares; M. A. Socinski; J. Shahidi; R. R. Hozak; V. Soldatenkova; N. Thatcher; F. Hirsch

doi:10.1016/S1556-0864(16)30326-4

1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

L. Paz-Ares
, M. A. Socinski
, J. Shahidi
, R. R. Hozak
, V. Soldatenkova
, N. Thatcher
, F. Hirsch

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	S153
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S1556-0864(16)30326-4
State	Published - Apr 2016
Externally published	Yes

Access to Document

10.1016/S1556-0864(16)30326-4

Cite this

Paz-Ares, L., Socinski, M. A., Shahidi, J., Hozak, R. R., Soldatenkova, V., Thatcher, N., & Hirsch, F. (2016). 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). Journal of Thoracic Oncology, 11(4), S153. https://doi.org/10.1016/S1556-0864(16)30326-4

Paz-Ares, L. ; Socinski, M. A. ; Shahidi, J. et al. / 1320_PR : Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). In: Journal of Thoracic Oncology. 2016 ; Vol. 11, No. 4. pp. S153.

@article{72cac369c3474e49874425d15bb18f8d,

title = "1320\_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)",

author = "L. Paz-Ares and Socinski, \{M. A.\} and J. Shahidi and Hozak, \{R. R.\} and V. Soldatenkova and N. Thatcher and F. Hirsch",

year = "2016",

month = apr,

doi = "10.1016/S1556-0864(16)30326-4",

language = "English",

volume = "11",

pages = "S153",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "4",

}

Paz-Ares, L, Socinski, MA, Shahidi, J, Hozak, RR, Soldatenkova, V, Thatcher, N & Hirsch, F 2016, '1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)', Journal of Thoracic Oncology, vol. 11, no. 4, pp. S153. https://doi.org/10.1016/S1556-0864(16)30326-4

1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). / Paz-Ares, L.; Socinski, M. A.; Shahidi, J. et al.
In: Journal of Thoracic Oncology, Vol. 11, No. 4, 04.2016, p. S153.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - 1320_PR

T2 - Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

AU - Paz-Ares, L.

AU - Socinski, M. A.

AU - Shahidi, J.

AU - Hozak, R. R.

AU - Soldatenkova, V.

AU - Thatcher, N.

AU - Hirsch, F.

PY - 2016/4

Y1 - 2016/4

UR - https://www.scopus.com/pages/publications/84995775066

U2 - 10.1016/S1556-0864(16)30326-4

DO - 10.1016/S1556-0864(16)30326-4

M3 - Article

AN - SCOPUS:84995775066

SN - 1556-0864

VL - 11

SP - S153

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Thatcher N et al. 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). Journal of Thoracic Oncology. 2016 Apr;11(4):S153. doi: 10.1016/S1556-0864(16)30326-4